| Title: |
Interruption or Discontinuation of Tyrosine Kinase Inhibitor Treatment in Chronic Myeloid Leukaemia: A Retrospective Cohort Study (SPARKLE) in Belgium. |
| Authors: |
Devos T.; Verhoef G.; Steel E.; Mazure D.; Lewalle P.; Bron D.; Berneman Z.; Benghiat FS.; MIneur P.; Theunissen K.; Zachée P.; Doyen C.; Put N.; LEJEUNE, Marie; Van Eygen K.; Havelange V.; Reusens M.; Pluymers W.; Peeters K. |
| Source: |
Acta Haematologica, 142 (197-207) (2019) |
| Publisher Information: |
Karger |
| Publication Year: |
2019 |
| Collection: |
University of Liège: ORBi (Open Repository and Bibliography) |
| Subject Terms: |
Chronic myeloid leukaemia; Tyrosine kinase inhibitor; Treatment interruption/discontinuation; Molecular response; Imatinib; Nilotinib; Dasatinib; Ponatinib; Human health sciences; Hematology; Sciences de la santé humaine; Hématologie |
| Description: |
peer reviewed ; Objectives: To assess interruptions/discontinuations of tyrosine kinase inhibitor (TKI) treatment in Belgian patients with chronic myeloid leukaemia (CML). Methods: This retrospective study included patients with TKI interruptions/discontinuations of ≥4 continuous weeks (no clinical trial context) between May 2013 and May 2016. Data collection took place between October 2016 and February 2017. Results: All 60 participants (69 interruptions/discontinuations) had chronic-phase CML and 75% had at least a major molecular response (≥MMR) at interruption/discontinuation. Most interruptions/discontinuations occurred while on imatinib (36/69; 49%) and dasatinib (20/69; 29%). Most interruptions/ discontinuations occurred due to side effects/intolerance (46/69; 67%); other reasons included a wish to conceive (6/69; 9%) and attempts to achieve treatment-free remission (TFR) (6/69; 9%). Interruptions due to side effects occurred later for imatinib- or dasatinib-treated patients than for those on nilotinib or ponatinib. Treatment was re-initiated in 62% (43/69) of cases. Most interruptions caused by side effects/intolerance were followed by treatment changes. All 4 patients with ≥MR 4.5 at interruption/discontinuation and ≥11-month follow-up who had not restarted treatment maintained the response. Conclusion: Although TKIs are used for long-term CML treatment, physicians sometimes recommend interruptions/discontinuations. In this study, interruptions/discontinuations were mainly caused by side effects or intolerance, rather than TFR attempts. |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| ISSN: |
0001-5792; 1421-9662 |
| Relation: |
urn:issn:0001-5792; urn:issn:1421-9662; https://orbi.uliege.be/handle/2268/255107; info:hdl:2268/255107; https://orbi.uliege.be/bitstream/2268/255107/1/499329.pdf; info:pmid:31163431 |
| DOI: |
10.1159/000499329 |
| Availability: |
https://orbi.uliege.be/handle/2268/255107; https://orbi.uliege.be/bitstream/2268/255107/1/499329.pdf; https://doi.org/10.1159/000499329 |
| Rights: |
open access ; http://purl.org/coar/access_right/c_abf2 ; info:eu-repo/semantics/openAccess |
| Accession Number: |
edsbas.8DDDF75A |
| Database: |
BASE |